Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR6508 injection in hemodialysis patients with secondary hyperparathyroidism
CTR20241908Phase 3Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of SHR6508 in secondary hyperparathyroidism (SHPT), chronic kidney disease (CKD), sponsored by Hengrui Therapeutics. Started Jun 2024; status: completed.
02
Drugs
SHR6508
03
Conditions
secondary hyperparathyroidism (SHPT)chronic kidney disease (CKD)
Beyond the preview
Go deeper on CTR20241908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241908.